New drug combo may beat BK virus in kidney transplants
NCT ID NCT03216967
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether switching from one immunosuppressant to everolimus, along with lowering overall immunosuppression, helps clear BK virus better than just lowering immunosuppression alone. The trial involved 130 kidney transplant recipients with BK virus in their blood. The goal was to see if more patients cleared the virus after 6 months while keeping their kidney function stable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus
What this could lead to
If successful, this could offer a safer way to clear BK virus after kidney transplant, reducing the risk of kidney damage without increasing rejection.
What could go wrong
This is a completed Phase 4 trial with 130 participants, so results are available but may not apply to all patients. Everolimus can cause side effects like mouth sores, infections, or metabolic issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BK VIRUS NEPHROPATHY AFTER KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP - Hôpital Georges Pompidou
Paris, 75908, France
-
AP-HP Hôpital Necker
Paris, 75743, France
-
CHRU - Hôpital Bretonneau
Tours, 37044, France
-
CHRU d'Angers
Angers, 49033, France
-
CHU - Hôpital Dupuytren
Limoges, 87042, France
-
CHU - Hôpital Maison Blanche
Reims, 51092, France
-
CHU - Hôpital Sud
Amiens, 80054, France
-
CHU - Hôpital de la Cavale Blanche
Bois-Guillaume, 76230, France
-
CHU - Hôpital de la Cavale Blanche
Brest, 29609, France
-
CHU Côte de Nacre
Caen, 14033, France
-
CHU Hôpital Gabriel Montpied
Clermont-Ferrand, 63000, France
-
CHU Poitiers - Hôpital Jean Bernard
Poitiers, 86021, France
-
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
Hôpital Edouard Herriot
Lyon, 69003, France
-
Les Hôpitaux Universitaires
Strasbourg, 67000, France